Melanie Aitken

Melanie Aitken is the Managing Principal of Bennett Jones (US) LLP. She is also co-head of the competition and foreign investment practice of Bennett Jones. She specializes in global antitrust and competition law and litigation.

Melanie served as Canada’s Competition Commissioner, in charge of the Canadian Competition Bureau from 2009 to 2012, having previously served as the Senior Deputy Commissioner leading merger review from 2006 to 2009.

While serving as Commissioner, Melanie led many high-profile civil and criminal matters and worked extensively with leaders of international antitrust authorities around the world on enforcement and policy cases, holding leadership roles in key international organizations, such as the Steering Committee of the International Competition Network.

Melanie was a partner at Bennett Jones and Davies Ward Philips & Vineberg before joining the Bureau in 2005. She has acted as counsel in the Supreme Court of Canada and represented the merging parties in Canada’s leading efficiencies case, Superior Propane. Melanie has an active antitrust advisory, trial and commercial practice, representing major Canadian and US companies in significant matters across a broad range of industries.

Melanie is a frequent speaker and commentator on competition issues, and has taught as an Adjunct Professor at Osgoode Hall and Queen’s Law Schools. She is active on the C.D. Howe Institute’s Competition Policy Council, and sits on the Advisory Boards of the Global Antitrust Institute, Schulich School of Business (Toronto, Canada), and W@CompetitionAmericas, and has been appointed a Fellow of the American Bar Foundation. Melanie also serves as a non-governmental advisor to the International Competition Network.

(Transcript) Protecting Intellectual Property for National Security: A Conversation with Rep. Nathaniel Moran (R-TX)

This transcript is from a CSIS and LeadershIP event hosted on December 3, 2024. Watch the full video here. John J. Hamre: Good afternoon, everybody. Welcome. We’re delighted to have you here. My name is John Hamre. I’m the president at CSIS. And this is going to be one
Read More

Generic Drugs, Property Rights, and the Orange Book

By Chris Borges Intellectual property (IP) rights secured through patents facilitate the introduction of dozens of new brand-name drugs and hundreds of generic drugs annually in the United States. However, proposals advanced by the Biden administration have mistakenly singled out patents as the cause of high drug prices, potentially harming the dense networks
Read More

Intellectual Property Rights and the Future of U.S. Technological Leadership

By Dr. Kirti Gupta This commentary is part of a report from the CSIS Economic Security and Technology Department, titled Staying Ahead in the Global Technology Race. The report features a set of essays outlining key issues on economic security for the next administration, including global technology competition, industrialization
Read More